Welcome to our dedicated page for Dolby Laboratories SEC filings (Ticker: DLB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dolby Laboratories, Inc. (NYSE: DLB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports, quarterly updates, proxy materials, and current reports on material events. As a Delaware corporation with Class A common stock listed on the New York Stock Exchange, Dolby files documents such as Form 10-K, Form 10-Q, Form 8-K, and the Definitive Proxy Statement (DEF 14A) with the U.S. Securities and Exchange Commission.
Dolby’s filings offer detailed insight into its licensing-focused business model, which centers on technologies like Dolby Atmos, Dolby Vision, Dolby Cinema, Dolby OptiView, and related audio and imaging intellectual property. In its proxy statement and other filings, the company discusses its single reportable segment, the importance of royalty-based revenue, and the role of cinema hardware and premium cinema technologies in its overall revenue mix.
Through current reports on Form 8-K, Dolby discloses financial results, dividends, and executive compensation plans. These filings cover quarterly and annual revenue, net income, non-GAAP metrics, and capital return actions such as cash dividends on Class A and Class B common stock. They also describe executive bonus plans that tie incentive payouts to non-GAAP operating income, revenue, and other performance metrics.
The Definitive Proxy Statement (DEF 14A) provides information on corporate governance and executive compensation, including proposals for the election of directors, advisory votes on named executive officer compensation, and ratification of the independent registered public accounting firm. It also summarizes non-GAAP financial measures and includes reconciliations to GAAP in appendices.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, highlight key figures and themes, and make it easier to understand Dolby’s financial condition, risk disclosures, and governance practices. Investors can use this page to follow Dolby’s official communications to regulators, monitor dividend and capital allocation decisions, and review the frameworks used to evaluate and reward the company’s leadership.
The Vanguard Group filed Amendment No. 14 to a Schedule 13G/A reporting Dolby Laboratories Inc. common stock and states it beneficially owns 0 shares representing 0% of the class.
The filing explains an internal realignment effective January 12, 2026, that disaggregated certain Vanguard subsidiaries and business divisions for reporting under SEC Release No. 34-39538; the filing is signed by Ashley Grim, Head of Global Fund Administration.
Dolby Laboratories, Inc. insider reporting centers on indirect holdings controlled through family trusts. On February 25, 2026, the Dagmar Dolby Trust contributed 1,000,000 shares of Class B Common Stock to a newly formed grantor retained annuity trust, described as a transfer for no value for tax and estate planning purposes. On the same date, the Dagmar Dolby Trust also converted 10,000 shares of Class B into 10,000 shares of Class A and gifted all those Class A shares to an unaffiliated charitable organization at no cost. Voting and investment power over various Class B positions is allocated among special trustees and LLC managers, and Dagmar Dolby disclaims beneficial ownership beyond her pecuniary interest.
Dolby Laboratories, Inc. executive Shriram Revankar reported an open-market sale of company stock. On 02/17/2026, he sold 3,000 shares of Class A common stock at $66.14 per share. After this transaction, he beneficially owned 83,218 Class A shares, including 59,172 shares underlying restricted stock units that may be forfeited if they do not vest.
Dolby Laboratories executive Ryan Nicholson, VP, CAO and Corporate Controller, reported an option exercise and share sale. On 02/13/2026 he exercised an employee stock option for 2,667 shares of Class A common stock at an exercise price of $45.50 per share, converting the derivative into common stock.
That same day, he sold 2,667 Class A shares in open-market transactions at a weighted average price of $66.3752 per share, in trades ranging from $66.37 to $66.39. After these transactions, he directly owns 36,956 Class A shares, including 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories has a holder planning to sell 3,000 shares of its common stock under Rule 144. The planned sale through Morgan Stanley Smith Barney has an aggregate market value of $198,420.00, with 60,884,768 Dolby common shares outstanding and trading on the NYSE.
The 3,000 shares to be sold were acquired as restricted stock from the issuer on 05/16/2024. The form also notes that the same person, identified as Revankar, sold 3,000 Dolby common shares on 11/21/2025 for gross proceeds of $196,650.00.
Dolby Laboratories’ controlling shareholders report a small reduction in their stake driven by charitable giving. An amended beneficial ownership report from Dagmar Dolby, family members and related trusts shows their combined percentage of outstanding Class A common stock has fallen by more than one percent.
The change comes mainly from gifts of 43,500 Class A shares by the Dagmar Dolby Fund and 890,000 Class A shares by the Dagmar Dolby Trust, partially offset by 3,140 Class A shares issued to David E. Dolby upon vesting of restricted stock units. After these moves, Dagmar Dolby beneficially owns 34,368,358 shares of Class A (assuming conversion of Class B), or 36.0% of that class, representing 84.0% of total voting power. David E. Dolby beneficially owns 33,615,951 such shares, or 35.2% of Class A, representing 82.3% of total voting power.
Dolby Laboratories, Inc. insider trust reports share conversion and charitable gift. On February 11, 2026, the Dagmar Dolby Trust converted 380,000 shares of Class B Common Stock into 380,000 shares of Class A Common Stock at no cost to the holder. Immediately afterward, the trust made a bona fide gift of all 380,000 Class A shares to an unaffiliated charitable organization, leaving that trust with no Class A shares from this transaction. The filing also lists large remaining indirect holdings of convertible Class B Common Stock across several Dolby family trusts and LLCs, all of which are convertible into Class A on a 1‑for‑1 basis.
Dolby Laboratories has a holder planning to sell 2,667 shares of its common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $177,022.66 and 60,884,768 shares outstanding.
The shares come from a stock option exercise dated February 13, 2026, paid in cash on the same date. The person for whose account the shares will be sold represents that they are not aware of any undisclosed material adverse information about Dolby’s current or prospective operations.
Morgan Stanley, Atlanta Capital Management, and Eaton Vance Atlanta Capital SMID-Cap Fund filed an amended Schedule 13G reporting significant holdings of Dolby Laboratories, Inc. Class A common stock.
Morgan Stanley reports beneficial ownership of 6,192,241 shares, or 10.2% of the class. Atlanta Capital reports 5,226,244 shares, or 8.6%, and the Eaton Vance Atlanta Capital SMID-Cap Fund reports 3,965,479 shares, or 6.5%. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Dolby.
Dolby Laboratories President and CEO Kevin J. Yeaman, who is also a director, reported an internal transfer of employee stock options rather than a market trade. On February 5, 2026, an option covering 145,252 shares of Dolby Class A common stock with a $66.62 exercise price was moved from his direct ownership to the Kevin and Rachel Yeaman Family Trust, a revocable trust, for no consideration.
The filing notes this change was made for estate planning purposes and is exempt from Section 16(b) under Rule 16b‑5. The option was originally granted for 145,252 shares, with one-quarter vesting on the first anniversary of December 15, 2025 and the remaining shares vesting in equal monthly installments over the subsequent 36 months, and it expires on December 15, 2035.